pubs.acs.org/joc
that the water-soluble 14-azacamptothecin (4), a hybrid be-
Intramolecular Formal [4 + 2] Cycloaddition of
Nitriles with Amides Triggered by TMSOTf/Et3N:
Highly Efficient Construction of Pyrrolo[1,2-a]-
pyrimidin-4(6H)-ones
tween luotonin A and the naturally occurring antitumor agent
camptothecin, is also a potent DNA topoisomerase I poison.4
The synthesis of luotonin A and analogues has thus drawn
much attention.5,6 However, most of the literature works
were centered at the construction of the skeleton with an
aromatic E-ring, while few methods were known for the
synthesis of the analogues with a saturated E-ring (as in 3
and 4). Hecht et al. reported the preparation of 3 via the
condensation of 1,2-dihydropyrrolo[3,4-b]quinolin-3-one
with a β-aminoacrylate.3c However, the yield was only 6%.
The intramolecular aryl radical addition to the CdN bond of
pyrimidin-4-ones to form the 5-membered pyrrole ring was
also found to be of low efficiency.4b,4c More recently, Mala-
cria and co-workers reported the one-step construction of
the pyrrolopyrimidinone skeleton via a radical cyclization
cascade with the acyclic N-acyl-N-(2-iodobenzyl)cyana-
mides as the precursors.6c Owing to the important biological
activity of luotonin A derivatives, it is certainly highly
desirable to develop general and efficient methods for their
synthesis. Herein, we report that the trimethylsilyl triflate/
triethylamine-triggered intramolecular reactions between
arylnitriles and acrylamides or β-ketoamides via a formal
[4+2] cycloaddition manner provide a convenient and effi-
cient entry to the synthesis of pyrrolopyrimidinones.
Feng Liu and Chaozhong Li*
Key Laboratory of Synthetic Chemistry of Natural
Substances, Shanghai Institute of Organic Chemistry, Chinese
Academy of Sciences, 345 Lingling Road, Shanghai 200032,
P. R. China
Received May 1, 2009
By treatment with TMSOTf/Et3N, N-(2-cyanoaryl-
methyl)-substituted acrylamides or β-ketoamides under-
went N-addition cascades under mild conditions to afford
the corresponding pyrrolo[1,2-a]pyrimidin-4(6H)-ones as
the formal [4 + 2] cycloaddition products in high yields.
Pyrrolo[1,2-a]pyrimidin-4(6H)-ones, especially the [7,8]-aryl-
fused ones (1), are a class of heterocyclic compounds of
significant biological interest. A typical example is the naturally
occurring luotonin A (2) isolated from a Chinese medicinal
plant (Peganum nigellastrum) in 1997,1 which is a human DNA
topoisomerase I poison2 and exhibits potent cytotoxicity
against P-388 cells. A number of luotonin A analogues have
thus been evaluated for their ability to stabilize the covalent
binary complex formed between human topoisomerase I and
DNA.3 Among them, the 16,17,18,19-tetrahydroluotonin A (3)
also showed good concentration-dependent cytotoxicity, indi-
cating an aromatic E-ring is not essential for targeting
the topoisomerase I-DNA covalent binary complex.3c More
importantly, Hecht and co-workers have recently discovered
Our initial approach to pyrrolopyrimidinones was to
conduct the intramolecular amidyl radical addition to a
CtN bond as part of our systematic study on N-centered
radical cyclization reactions.7 This idea was vigorously
tested with N-(2-cyanobenzyl)but-2-enamide (5a) as the
(4) (a) Cheng, K.; Rahier, N. J.; Eisenhauer, B. M.; Thomas, S. J.; Gao,
R.; Hecht, S. M. J. Am. Chem. Soc. 2005, 127, 838. (b) Rahier, N. J.; Cheng,
K.; Gao, R.; Eisenhauer, B. M.; Hecht, S. M. Org. Lett. 2005, 7, 835. (c)
Elban, M. A.; Sun, W.; Eisenhauer, B. M.; Gao, R.; Hecht, S. M. Org. Lett.
2006, 8, 3513.
(5) For a review on the synthesis of luotonin A, see: Ma, Z.; Hano, Y.;
Nomura, T. Heterocycles 2005, 65, 2203.
(6) For the latest examples on the synthesis of luotonin A, see: (a)
Bowman, W. R.; Cloonan, M. O.; Fletcher, A. J.; Stein, T. Org. Biomol.
Chem. 2005, 3, 1460. (b) Tangirala, R.; Antony, S.; Agama, K.; Pommier, Y.;
Curran, D. P. Synlett 2005, 2843. (c) Servais, A.; Azzouz, M.; Lopes, D.;
Courillon, C.; Malacria, M. Angew. Chem., Int. Ed. 2007, 46, 576. (d) Zhou,
H.-B.; Liu, G.-S.; Yao, Z.-J. J. Org. Chem. 2007, 72, 6270.
(7) (a) Tang, Y.; Li, C. Org. Lett. 2004, 6, 3229. (b) Chen, Q.; Shen, M.;
Tang, Y.; Li, C. Org. Lett. 2005, 7, 1625. (c) Lu, H.; Li, C. Tetrahedron Lett.
2005, 46, 3574. (d) Hu, T.; Shen, M.; Chen, Q.; Li, C. Org. Lett. 2006, 8, 2647.
(e) Lu, H.; Chen, Q.; Li, C. J. Org. Chem. 2007, 72, 2564. (f) Liu, F.; Liu, K.;
Yuan, X.; Li, C. J. Org. Chem. 2007, 72, 10231. (g) Yuan, X.; Liu, K.; Li, C. J.
Org. Chem. 2008, 73, 6166.
(1) Ma, Z.-Z.; Hano, Y.; Nomura, T.; Chen, Y.-J. Heterocycles 1997, 46,
541.
(2) Cagir, A.; Jones, S. H.; Gao, R.; Eisenhauer, B. M.; Hecht, S. M. J.
Am. Chem. Soc. 2003, 125, 13628.
(3) (a) Ma, Z.; Hano, Y.; Nomura, T.; Chen, Y. Bioorg. Med. Chem. Lett.
2004, 14, 1193. (b) Cagir, A.; Jones, S. H.; Eisenhauer, B. M.; Gao, R.; Hecht,
S. M. Bioorg. Med. Chem. Lett. 2004, 14, 2051. (c) Cagir, A.; Eisenhauer, B.
M.; Gao, R.; Thomas, S. J.; Hecht, S. M. Bioorg. Med. Chem. 2004, 12, 6287.
(d) Lee, E. S.; Park, J. G.; Kim, S. I.; Jahng, Y. Heterocycles 2006, 68, 151.
DOI: 10.1021/jo900907h
r
Published on Web 06/08/2009
J. Org. Chem. 2009, 74, 5699–5702 5699
2009 American Chemical Society